<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20030310164615</creation_date><modification_date>D:20030310164623+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_dec_8.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communitiesbrussels, 06/03/2003c(2003) 772
 not for publication</p></section><section><header>commission decisionof 06/03/2003
 amending decision c(1999) 939 on the marketing authorization for
 the medicinal product for human use
 &quot;cetrotide - cetrorelix (as acetate)&quot;
 (text with eea relevance)</header><p>only the english text is authentic.ii</p></section><section><header>commission decisionof 06/03/2003
 amending decision c(1999) 939 on the marketing authorization for
 the medicinal product for human use
 &quot;cetrotide - cetrorelix (as acetate)&quot;
 (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorization and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982, and inparticular article 10(2) thereof,
 having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot;cetrotide - cetrorelix (as acetate)&quot; entered in the
 community register of medicinal products under nos eu/1/99/100/001-003
 authorised by commission decision c(1999) 939 of 13 april 1999, as amended,
 complies with the requirements set out in regulation (eec) no 2309/93.
 (2)</p><p>serono europe ltd. submitted an application to change the package leaflet on 18
 december 2002 pursuant to article 61(3) of directive 2001/83/ec
 3.(3)</p><p>the proposed changes are not connected with the contents of the summary of
 characteristics of the medicinal product in question.
 (4)</p><p>the package leaflet as changed continues to comply with title v of directive
 2001/83/ec
 (5)</p><p>decision c(1999) 939 should therefore be amended accordingly.</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj l 88, 24.3.1998, p. 7.3 oj l 311, 28.11.2001, p. 67.iiihas adopted this decision:
 article 1a) annex iii b is replaced by the annex to this decision.article 2this decision is addressed to serono europe ltd., 56, marsh wall, london e14 9tp,united kingdom.
 done at brussels, 06/03/2003
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>